ABOUT THIS STUDY
- Macular edema secondary to BRVO involving the foveal center in male or female patients at least 18 years of age
- Duration of BRVO macular edema less than 6 months prior to baseline visit
- Best corrected ETDRS visual acuity 20/40-20/320 (Snellen equivalent) using the 4 meters testing method.
- Central foveal thickness greater than or equal to 250 microns using the OCT-3
- Less than 25% of foveal capillary ring disruption
- Less than 2 disc areas of capillary non-perfusion within 1000 microns of the foveal center
- Absence of hemorrhage or lipid in the foveal center
- Investigator comfortable deferring macular laser for 18 weeks from baseline and intravitreous steroid for 36 weeks from baseline
- Ocular conditions other than BRVO related macular edema such as significant cataract,
diabetic retinopathy, AMD, glaucoma, uveitis, epiretinal membrane, vitreomacular
traction or tumor.
- Intraocular surgery within past 3 months
- Significant enlargement of foveal avascular zone(>25% disruption of capillary ring) or
greater than 2 disc areas of nonperfusion within 1000 microns of foveal center.
- Likelihood of evidence driven indication for peripheral photocoagulation in the next 6
- Patients who have shown evidence of spontaneous improvement within the preceding 3
months, as determined by an improvement of >15 letters of vision or thinning of the
Center Point on OCT of >20% from baseline determination
- Prior grid laser within 4 months of baseline or more than one prior grid laser
- No prior intravitreous or periocular steroid injections in the study eye.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Los Angeles, California
- Hagerstown, Maryland
- West Columbia, South Carolina